CAR T-cell therapy for lupus nephritis that hasn't responded to standard treatment
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called C-CAR168, which uses your own immune cells to target and calm the part of the immune system attacking your kidneys. It is designed for people with lupus nephritis that has not improved with usual treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old and weigh at least 40 kg.
- You have been diagnosed with systemic lupus erythematosus (SLE).
- You have a kidney biopsy showing lupus nephritis (Class III or IV) within the last 6 months.
- Your lupus nephritis has not responded to standard therapy, and you are on a corticosteroid taper.
- You have positive antibodies (ANA, anti-dsDNA, or anti-Smith) in your blood.
- You do not have active infections (like hepatitis B, hepatitis C, HIV, or tuberculosis), are not pregnant or breastfeeding, and have not had prior gene therapy or CAR T-cell therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This trial tests a new treatment called ICG318 CAR-T, which uses your own immune cells to target and calm the overactive immune system in lupus. It may help people whose lupus has not improved with standard treatments, including those with lupus nephritis (kidney inflammation).
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
This trial tests a new treatment called CD19 CAR-T cell therapy for people with severe lupus nephritis (lupus-related kidney inflammation) that hasn't improved with usual treatments. The therapy uses your own immune cells to target and possibly reset the immune system, which may reduce kidney damage and help control the disease.
This study tests a new type of treatment called CAR-T cells, which are specially engineered immune cells that may help control lupus by targeting the cells causing the disease. If you have active lupus despite standard treatments, this therapy might offer a new option to reduce symptoms and improve your condition.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.